iBET is a world-leader in the development of complex biopharmaceuticals for innovative treatments for personalized medicine. Much of this investigation is carried out to obtain recombinant proteins for novel medications, by manipulating viral vectors for gene therapy and new vaccines, prophylactics and therapeutics.
iBET’s competencies have been broadened to include the application of stem cells to cellular therapy and regenerative medicine. Furthermore, iBET is drawing up new predictive models more closely representing what happens within the organism, essential contributions to toxicology research and pre-clinical trials of new drugs. Another focus at iBET is the design of new medications trough the study of human proteins. This offers great promise for advance against diseases such as cancer, diabetes among others, including genetic disorders.